Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications. Mr. Inchausti will oversee the company’s investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming.
A senior executive with over 25 years of strategic healthcare communications experience, Mr. Inchausti joins Ocugen from Novo Nordisk Inc., where he was Senior Director, Reputation & Brand, leading corporate media relations, executive visibility, reputation strategy and research, crisis and issues management and corporate communications for the US affiliate.
“Ken is joining us at a critical time where we are continuing our plans for obtaining regulatory approval for and potentially commercializing COVAXIN® in the US and Canada, as well as the planned initiation our Phase 1/2a clinical trial for OCU400. His talents and expertise will be key as we seek to find new ways of raising our profile with multiple stakeholders as a leader committed to global public health and fighting this pandemic, and also driving innovation through our gene therapy platform to find cures for leading causes of blindness,” said Sanjay Subramanian, MBA, Chief Financial Officer and Head of Corporate Development at Ocugen, Inc.
Mr. Inchausti has worked across multiple sectors within healthcare – from pharmaceuticals to hospitals and providers to patient advocacy. Prior to Novo Nordisk, he held communications positions at GSK, Premier, Inc., Fleishman Hillard, and the American Diabetes Association.
Mr. Inchausti holds a bachelor’s degree in Communications from Old Dominion University.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.